FindTrial
Sign In

Ixekizumab a new treatment for plaque psoriasis

Real world efficacy and safety of Ixekizumab in moderate to severe plaque psoriasis in Indian population - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/02/081205
Enrollment
50
Registered
2025-02-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-03-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L400- Psoriasis vulgaris

Interventions

Intervention1: Ixekizumab Injection: Ixekizumab injection will be given as per schedule (0,2,4,6,8,10,12,16,20 & 24 weeks) to patients of psoriasis vulgaris. Efficacy and safety will be monitored. Tot

Sponsors

Commandant Base Hospital Delhi Cantt
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult patients Moderate-to-severe chronic plaque psoriasis

Exclusion criteria

Exclusion criteria: Children below 18yrs Pregnant or lactating ladies Active Infections

Design outcomes

Primary

MeasureTime frame
Monitoring of PASI at 4,16 and 24 weeksTimepoint: 4,16 and 24 week—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

India

Contacts

Public ContactTeghveer singh

Base Hospital Delhi Cantt (Army College Of Medical Science)

tegveersingh@gmail.com09709029215

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jul 23, 2026